Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Approximately 15%-20% of all non-small cell lung cancer (NSCLC) cases present with stage I disease. Surgical resection traditionally offers the best chance of a cure but some patients will not have this treatment due to older age, comorbidities or personal choice. Stereotactic ablative radiotherapy (SABR) has become an established curative intent treatment option for patients who are not selected for or do not choose surgery. The aim of this study is to compare survival at 90 days, 6 months, 1 year and 2 years for patients who received either lobectomy or SABR.
Methods: We used data from the 2015 National Lung Cancer Audit database and linked with Hospital Episode Statistics and the radiotherapy dataset to identify patients with NSCLC stage IA-IB and performance status (PS) 0-2 who underwent surgery or SABR treatment. We assessed the likelihood of death at 90 days, 6 months, 1 year and 2 year after diagnosis and procedure date to observe survival between two patient groups.
Results: We identified 2373 patients in our cohort, 476 of whom had SABR. The median difference between date of diagnosis and date of treatment for surgery patients was 17 days while for SABR patients it was 73 days. Increasing age and worsening PS were associated with having SABR rather than surgery. Survival between the two treatment modalities was similar early on but by 1-year people who had surgery did better than those who had SABR (adjusted ORs 2.12, 95% CI 1.35 to 2.31). This difference persisted at 2 years and when the analysis was restricted to patients aged <80 years and with PS 0 or 1 and stage IA only.
Conclusion: Our analysis suggests that patients who have lobectomy have a better survival compared with SABR patients; however, we found considerable delays in patients receiving SABR which may contribute to poorer long-term outcomes with this treatment option. Reducing these delays should be a key focus in development and reorganisation of services.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/thoraxjnl-2018-212493 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Single-Cell RNA Sequencing Reveals Potential Mechanism of RUNX3 Reshaping Tumor Microenvironment in Non-small-cell Lung Cancer.
Ann Surg Oncol
September 2025
Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China.
Background: RUNX3 acts as a tumor suppressor gene in non-small-cell lung cancer (NSCLC), yet its specific biological mechanism is still unclear. This study aimed to uncover tumor microenvironment (TME) changes in NSCLC with varying RUNX3 expression statuses through single-cell RNA sequencing.
Patients And Methods: In total, seven patients with NSCLC with detailed pathological data were involved, with three both paracancerous and cancerous tissue samples.
Practice Pattern Variability in the Use of Pulmonary Arterial Catheters in Cardiac Surgery.
J Cardiothorac Vasc Anesth
August 2025
Department of Anesthesiology and Critical Care, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Objectives: To quantify intraoperative pulmonary arterial catheter (PAC) use during cardiac surgery and identify hospital-, anesthesiologist-, and patient-level factors associated with PAC utilization.
Design: A cross-sectional, observational study using generalized logistic mixed models to examine variations in PAC use.
Setting: Fifty-three US academic hospitals participating in the Multicenter Perioperative Outcomes Group (MPOG) national registry PARTICIPANTS: 145,343 adult patients undergoing cardiac surgery between January 1, 2016, and December 31, 2022.
KRAS mutations in Non-Small Cell Lung Cancer: translational aspects, current therapies and challenges for future research.
Crit Rev Oncol Hematol
September 2025
Unit of Cancer Genetics, Institute of Genetic & Biomedical Research (IRGB), National Research Council (CNR), Traversa La Crucca n. 3, 07100, Sassari, Italy; Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari, Viale San Pietro 43, 07100, Sassari, Italy. Electronic address: gpalmier
Mutations in the KRAS gene are prominent oncogenic drivers in non-small cell lung cancer (NSCLC), with multiple pathophysiological, clinical and prognostic implications. Although historically considered an "undruggable" target, recent research led to the development of specific KRAS-G12C inhibitors, like sotorasib and adagrasib which are currently approved for clinical use in patients affected by advanced NSCLC. However, the clinical utility of these drugs is often limited by resistance development through several biological mechanisms, including additional KRAS mutations, activation of compensatory pathways and metabolic reprogramming.
View Article and Find Full Text PDFAssessing Malnutrition in Lung Cancer Resection Patients: Modification of Global Leadership Initiative on Malnutrition (GLIM) Criteria for Implementation in Surgical Practice.
Clin Nutr ESPEN
September 2025
Duke University, Department of Surgery, Division of Trauma, Acute, and Critical Care Surgery, Durham, NC, USA. Electronic address:
Background: Up to 70% of lung cancer may be malnourished. This study aims to examine the effects of malnutrition on outcomes in lung cancer patients undergoing resection using modified GLIM criteria.
Methods: The study utilized the mGLIM criteria to identify malnourished patients.
Effects of virtual reality-guided imagery relaxation intervention in improving anxiety among lung cancer patients:A Randomized Controlled Trial.
Asian Nurs Res (Korean Soc Nurs Sci)
September 2025
The Fourth Affiliated Hospital of Hebei Medical University; Address: The Fourth Affiliated Hospital of Hebei Medical University, No. 12 Jiankang Road, Chang'an District, Shijiazhuang City, Hebei Province, 050000, People's Republic of China. Electronic address:
Purpose: To examine the effectiveness of virtual reality (VR)-guided imagery relaxation (VRGI) intervention in reducing anxiety among lung cancer surgery patients.
Methods: A randomized clinical trial was conducted at the Fourth Affiliated Hospital of Hebei Medical University (Shijiazhuang, Hebei, China) to recruit patients scheduled for their first elective endoscopic lung cancer surgery under general anesthesia between December 2023 and March 2024. Patients were randomly assigned in a 1:1 ratio to either the control group, receiving routine treatment and staged care in thoracic surgery, or the experimental group, receiving VRGI intervention in addition to the control group's protocol.